| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Co N.V. | Chief Commercial Officer | Ordinary Shares | 43K | $1.1M | $25.54 | Jan 7, 2025 | Direct |
| NewAmsterdam Pharma Co N.V. | Chief Commercial Officer | Option (right to buy) | 200K | Jan 2, 2025 | Direct | ||
| Annexon, Inc. | Director | Stock Option (Right to Buy) | 55K | Jun 5, 2025 | Direct | ||
| Akili, Inc. | Director | Stock Option (Right to Buy) | 22K | May 2, 2023 | Direct | ||
| Apogee Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 14.5K | Jun 17, 2025 | Direct | ||
| Biohaven Pharmaceutical Holding Co Ltd. | CCO-Migraine & Common Disease | Common Shares | 0 | Oct 3, 2022 | Direct | ||
| Biohaven Pharmaceutical Holding Co Ltd. | CCO-Migraine & Common Disease | Restricted Share Unit Award | 0 | Oct 3, 2022 | Direct | ||
| Biohaven Pharmaceutical Holding Co Ltd. | CCO-Migraine & Common Disease | Stock Options (Right to Buy) | 0 | Oct 3, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | Jun 17, 2025 | 1 | $0 | 4 | Jun 20, 2025 | Director |
| ANNX | Annexon, Inc. | Jun 5, 2025 | 1 | $0 | 4 | Jun 9, 2025 | Director |
| ANNX | Annexon, Inc. | Jan 9, 2025 | 1 | $0 | 4 | Jan 10, 2025 | Director |
| ANNX | Annexon, Inc. | Jan 9, 2025 | 0 | $0 | 3 | Jan 10, 2025 | Director |
| NAMS | NewAmsterdam Pharma Co N.V. | Jan 7, 2025 | 1 | $0 | 4 | Jan 7, 2025 | Chief Commercial Officer |
| NAMS | NewAmsterdam Pharma Co N.V. | Jan 2, 2025 | 1 | $0 | 4 | Jan 6, 2025 | Chief Commercial Officer |
| APGE | Apogee Therapeutics, Inc. | Jun 5, 2024 | 1 | $0 | 4 | Jun 7, 2024 | Director |
| NAMS | NewAmsterdam Pharma Co N.V. | Apr 25, 2024 | 0 | $0 | 3 | May 3, 2024 | Chief Commercial Officer |
| APGE | Apogee Therapeutics, Inc. | Jul 13, 2023 | 0 | $0 | 3/A | Jul 17, 2023 | Director |
| AKLI | Akili, Inc. | May 2, 2023 | 1 | $0 | 4 | May 4, 2023 | Director |
| AKLI | Akili, Inc. | Nov 2, 2022 | 1 | $0 | 4 | Nov 4, 2022 | Director |
| BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Oct 3, 2022 | 12 | -$2.11M | 4 | Oct 3, 2022 | CCO-Migraine & Common Disease |
| AKLI | Akili, Inc. | Aug 19, 2022 | 0 | $0 | 3 | Aug 19, 2022 | Director |
| BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Jan 6, 2022 | 8 | -$486K | 4 | Jan 7, 2022 | CCO-Migraine & Common Disease |
| BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Nov 25, 2021 | 3 | -$151K | 4 | Nov 26, 2021 | CCO-Migraine & Common Disease |